The Global Consortium on Immunotherapy:
HIV T-cell Immunotherapy
In 1991, Dr. Jonas Salk proposed an innovative approach in the control of HIV based upon an innovative technique called T-cell vaccination.
The T-cell treated patient, while remaining HIV positive, benefits from a 'live and let live' functional cure through immune system support, specifically the re-establishment of immunological memory. The patient remains asymptomatic, perhaps without the need for anti-retrovirals and the associated toxicity issues.
The Global Consortium for Immunotherapy, a collaborative effort between Hadassah University Hospital and Human Futures Foundation, was established in support of conducting clinical trials in humans of this ground-breaking immunotherapeutic technique in the treatment of autoimmune diseases including multiple sclerosis, rheumatoid arthritis, and HIV/AIDS through clinical trials in the United States.